Pepro Tech
Originally published online as doi:10.1189/jlb.0608347 on October 22, 2008

Published online before print October 22, 2008
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
jlb.0608347v1
85/1/132    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desplat-Jégo, S.
Right arrow Articles by Boucraut, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desplat-Jégo, S.
Right arrow Articles by Boucraut, J.
(Journal of Leukocyte Biology. 2009;85:132-135.)
© 2009 by Society for Leukocyte Biology

TWEAK is expressed at the cell surface of monocytes during multiple sclerosis

Sophie Desplat-Jégo*,1, Lionel Feuillet{dagger}, Rita Creidy*, Irina Malikova{dagger}, Roselyne Rance*, Michel Khrestchatisky*, Kyungmin Hahm{ddagger}, Linda C. Burkly{ddagger}, Jean Pelletier{dagger} and José Boucraut*

* Neurobiologie des Interactions Cellulaires et Neurophysiopathologie, Centre National de la Recherche Scientifique UMR 6184, IFR Jean Roche, and Pôle de Biologie, Laboratoire d’Immunologie, Hôpital de la Conception, Assistance Publique–Hôpitaux de Marseille, Marseille, France;
{dagger} Pôle de Neurosciences Cliniques, Service de Neurologie, Hôpital de la Timone, Marseille, France; and
{ddagger} Autoimmunity and Drug Discovery, Biogen Idec, Cambridge, Massachusetts, USA

1 Correspondence: NICN, CNRS UMR 6184, IFR Jean Roche, 51 Bd Pierre Dramard, 13 916 Marseille Cedex 20, France. E-mail: sophie.jego-desplat{at}ap-hm.fr

The TNF superfamily ligand, TNF-like weak inducer of apoptosis (TWEAK), regulates cellular responses ranging from proliferation to cell death in a manner highly dependent on the cell type and the microenvironmental context. We have shown previously that treatment of experimental autoimmune encephalomyelitis mice after the priming phase with neutralizing anti-TWEAK antibodies results in a reduction in the severity of the disease and leukocyte infiltration. To further characterize TWEAK/fibroblast growth factor-inducible 14-kDa protein (Fn14) involvement during multiple sclerosis (MS), we evaluated in MS patients and controls: TWEAK and Fn14 expression on PBMC and soluble TWEAK concentration in serum and cerebrospinal fluid (CSF). Thirty-six consecutive patients were enrolled, including 11 patients with relapsing-remitting MS, 11 with a clinical isolated syndrome suggestive of MS (CISSMS), and 14 controls with non-MS diseases. Intracellular TWEAK could be observed in lymphocytes and/or monocytes in all groups of patients. None of the 36 patients displayed TWEAK expression at the cell surface of lymphocytes. In contrast, 12 out of the 36 patients were positive for membrane TWEAK expression on their monocytes. Among these patients, eight were from the CISSMS group. Fn14 was not detected in PBMC. The soluble form of TWEAK is detectable in serum and CSF of patients, and TWEAK concentrations were not statistically different between the disease groups. We demonstrated for the first time that TWEAK is expressed at the cell surface of monocytes during MS, especially in the CISSMS group. Our results support the proposal that TWEAK could be a target for antibody therapy in MS.

Key Words: inflammation • cytokine • central nervous system